Status:
RECRUITING
STUDY INCIDENCE AND CHARACTERISTICS OF MALIGNANT NEOPLASIES IN PATIENTS WITH HEMOGLOBINOPATHY FOLLOWED IN ITALY
Lead Sponsor:
Società Italiana Talassemie ed Emoglobinopatie
Conditions:
Malignacy, Hemoglobinopathie
Eligibility:
All Genders
18-100 years
Brief Summary
The Trial aims to increase the information available on the relevance of tumor pathology in hemoglobinopathies, updating the data relating to hepatocarcinoma and investigating which other tumors are m...
Detailed Description
By providing targeted screening strategies, these data may contribute to the early identification of tumor pathology in hemoglobinopathies, and, by contributing to the identification of risk factors, ...
Eligibility Criteria
Inclusion
- Transfusion-dependent or independent beta-thalassemia, hemoglobin H disease, sickle cell anemia and microdrepanocytosis
- Current or previous malignant tumor pathology
- Availability of medical history including the most relevant clinical and instrumental data before the onset of cancer
Exclusion
- \- Other haematological diseases other than hemoglobinopathies
- Absence of neoplastic events in the clinical history
- Non-availability of relevant clinical and instrumental data
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 28 2052
Estimated Enrollment :
10000 Patients enrolled
Trial Details
Trial ID
NCT05286138
Start Date
February 1 2022
End Date
February 28 2052
Last Update
April 1 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Azienda Ospedaliera Universitaria Di Cagliari
Cagliari, Italy, 09121